Amsterdam, The Netherlands, March 20, 2017, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces the appointment of Jan Feijen as Chief Operations Officer (COO) effective from April 1, 2017.
Jan Feijen brings significant professional management skills and extensive experience in manufacturing, operations and project management to Kiadis Pharma. He is a seasoned leader who, most recently, was Vice President Manufacturing and Technical Operations Platform Lead Vaccines and Advanced Therapies at Janssen (Pharmaceutical Companies of Johnson & Johnson). Prior to that he held various executive and project lead positions at Crucell, Avebe and Gist Brocades. Jan has built and run many clinical and commercial manufacturing facilities and operations across multiple sites in Europe, the US and Asia. In his role as COO at Kiadis Pharma, Jan will be responsible for manufacturing, supply chain, QA and project management.
Arthur Lahr, CEO designate of Kiadis Pharma, said: “We are very pleased that an industry leader like Jan has accepted this opportunity to join Kiadis Pharma. His vast experience in pharma production precedes him, and his experience in running complex, just-in-time logistics will be of great value in scaling up our patient specific supply chain. I have known Jan for many years and he is one of those few people that can thrive in both large and small organizations. I am confident that Jan will ensure the smooth running of our Phase III operations and will successfully set up and run our commercial supply chain.”
Commenting on his appointment Jan Feijen said: “I am very pleased to be joining Kiadis Pharma at this important time in its development. With the Company’s pivotal Phase III trial with ATIR101™ now underway, it is vital that the necessary steps are taken to ensure everything continues to run smoothly and that we have all logistics in hand ready to roll out commercially in the future.”
